Episode
CAR-T in 2025: Advancements and the Road Ahead
- Podcast
- Treating Blood Cancers
- Published
- Feb 14, 2025
- Duration seconds
- 2292
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/treating-blood-cancers-14318/episodes/car-t-in-2025-advancements-and-the-road-ahead/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/treating-blood-cancers-14318/car-t-in-2025-advancements-and-the-road-ahead.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Jason Westin, M.D., MS, FACP, MD Anderson Cancer Center, Houston, TX Recorded on January 21, 2025 Jason Westin, M.D., MS, FACP Professor, Department of Lymphoma & Myeloma Lead, Lymphoma & Myeloma Service Line Director, Lymphoma Clinical Research Section Chief, Aggressive and Indolent Lymphoma MD Anderson Cancer Center Houston, TX In this episode, Dr. Jason Westin from MD Anderson Cancer Center in Houston, Texas explores CAR T-cell therapy, covering both current and emerging indications. He highlights the educational needs of patients and caregivers, as well as the essential role of community and academic collaboration before and after treatment. Dr. Westin also discusses the use of minimal/measurable residual disease (MRD) in treatment planning, future directions of CAR-T, and ongoing clinical trials. Tune in to stay up-to-date on the latest advancements in CAR T-cell therapy! This episode is supported by Allogene Therapeutics, Bristol Myers Squibb, Johnson & Johnson & Legend Biotech, and Kite, a Gilead Company.